Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Read →
Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance s
article · Oct 2026
High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis.
Read →
We review and report the use of high-dose bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP) in pediatric patients. We included all patients with pediatric-onset RRP who underwent bevacizumab (25 mg/mL) injections b
article · Oct 2026
HPV Strain Predicts Severity of Juvenile-Onset Recurrent Respiratory Papillomatosis with Implications for Disease Screening
Read →
Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is the most common benign neoplasm of the larynx in children, presenting with significant variation in clinical course and potential for progression to malignancy. Since JoRRP is d
article · Oct 2026
Patient-Derived Organotypic Epithelial Rafts Model Phenotypes in Juvenile-Onset Recurrent Respiratory Papillomatosis
Read →
Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is driven by human papillomavirus (HPV) low-risk strains and is associated with significant morbidity. While previous studies of 2D cultures have shed light on disease pathogenesis
article · Oct 2026
Summaries and takeaways+ Show
Summary of this collection+ Show
Key points+ Show
Featured picks for families are being prepared — the summaries above are written for you.
Takeaways+ Show
The doctors in this collection+ Show
All expert statements+ Show
Expert statements from the recordings in this collection.
What's new+ Show